Schayowitz Adam
EVP, Head of R&D
Schayowitz Adam has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Oct 9, 2026.
On the most recent filing, Schayowitz Adam is listed as EVP, Head of R&D at Zymeworks Inc. Inside the rolling window, Schayowitz Adam reported no open-market purchases and 1 open-market sale totaling $358K in ZYME.
Companies traded
Other insiders at ZYME
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$358K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Schayowitz Adam made?
Schayowitz Adam has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.
Which companies does Schayowitz Adam trade?
Schayowitz Adam has filed SEC Form 4 disclosures for 1 company, including ZYME.
When was Schayowitz Adam's most recent SEC Form 4 filing?
Schayowitz Adam's most recent SEC Form 4 filing on Tracefour is dated Oct 9, 2026.
What is Schayowitz Adam's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Schayowitz Adam is listed as EVP, Head of R&D.
What is Schayowitz Adam's total buy and sell value in the current window?
Inside the rolling retention window, Schayowitz Adam bought $0 and sold $358K based on SEC Form 4 filings.
What was Schayowitz Adam's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 13,832 ZYME shares on 2026-10-09, worth $358K, per SEC Form 4 filings.